A detailed history of Manufacturers Life Insurance Company, The transactions in Savara Inc stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 44,956 shares of SVRA stock, worth $143,859. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,956
Previous 41,250 8.98%
Holding current value
$143,859
Previous $166,000 14.46%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.96 - $5.07 $14,675 - $18,789
3,706 Added 8.98%
44,956 $190,000
Q2 2024

Aug 14, 2024

BUY
$3.66 - $5.34 $19,526 - $28,488
5,335 Added 14.85%
41,250 $166,000
Q3 2023

Nov 15, 2023

BUY
$2.97 - $3.88 $5,515 - $7,205
1,857 Added 5.45%
35,915 $135,000
Q2 2023

Aug 11, 2023

BUY
$1.69 - $3.24 $57,558 - $110,347
34,058 New
34,058 $108,000
Q3 2020

Nov 09, 2020

SELL
$1.09 - $2.21 $32,679 - $66,258
-29,981 Closed
0 $0
Q2 2020

Aug 10, 2020

BUY
$1.8 - $3.05 $9,990 - $16,927
5,550 Added 22.72%
29,981 $81,000
Q1 2020

May 15, 2020

BUY
$1.91 - $4.08 $46,663 - $99,678
24,431 New
24,431 $52,000
Q2 2019

Aug 14, 2019

SELL
$2.37 - $11.7 $27,373 - $135,135
-11,550 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$6.71 - $8.6 $8,582 - $10,999
1,279 Added 12.45%
11,550 $85,000
Q4 2018

Feb 14, 2019

SELL
$6.27 - $10.92 $8,821 - $15,364
-1,407 Reduced 12.05%
10,271 $78,000
Q3 2018

Nov 14, 2018

SELL
$10.49 - $12.87 $91,514 - $112,277
-8,724 Reduced 42.76%
11,678 $130,000
Q2 2018

Aug 14, 2018

BUY
$8.55 - $13.76 $166,434 - $267,852
19,466 Added 2079.7%
20,402 $230,000
Q1 2018

May 15, 2018

BUY
$8.99 - $14.95 $979 - $1,629
109 Added 13.18%
936 $9,000
Q4 2017

Feb 08, 2018

BUY
$8.26 - $16.76 $6,831 - $13,860
827
827 $12,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.